Abstract 381P
Background
The most frequent and aggressive primary brain malignancy in adults is a glioblastoma multiforme (GBM) which is frequently resistant to apoptosis-inducing chemotherapeutic agents. Surface exposure of phosphatidylserine (PS) is a universally recognized apoptotic phenomenon. Although in acute myeloid leukemia and T-cell lymphoma cells Xkr8 mediates PS exposure in response to apoptotic stimuli, the mechanisms underlying the regulation of Xkr8 expression remain unclear. Nevertheless, the loss of Xkr8 in blood cancer cells blocks cell-surface exposure of PS and causes dramatic decreasing of engulfment by phagocytes. Whether Xkr8 is dysregulated in specific cancers and contribute to the survival of patients has not been investigated. This study was aimed to investigate the association of overall survival (OS) and disease-free survival (DFS) with expression and copy number alterations (CNA) of XKR8 gene in GBM patients.
Methods
Data of gene expression, CNA and clinical information from 619 GBM tumors were obtained from TCGA Glioblastoma Multiforme study using the open platform CBioPortal. Among all cases, 572 GBM samples were with CNA (GISTIC 2.0. Values) data and 162 samples were with mRNA expression data (RNA Seq V2 RSEM). Patients were divided into two groups taking into account CNA or expression of mRNA. XKR8 expression was scored as downregulated when mRNA value was lower than the mean expression + standard deviation. XKR8 gene was marked as amplified when CNA value was equal 1 or 2. Kaplan-Meier and log-rank analyses were performed using RStudio.
Results
Survival analysis in GBM patients showed that the OS (p-value=0,015) of the group with downregulated XKR8 mRNA expression (n = 22) was better than of group with normal and upregulated expression (n = 140). Equivalent results have been shown for DFS, where the patients with low XKR8 expression (n = 15) had a weaker risk of disease recurrence (p-value=0,003) than other GBM patients (n = 103). Also, the OS of GBM patients with amplified XKR8 gene (n = 83) was worse (p-value=0,049) than of patients with other CNAs (n = 489).
Conclusions
Thus XKR8 gene can be characterized as prognostic biomarker of survival and disease progression in GBM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Research Laboratory "Biomarker" IFMB KFU.
Funding
Russian Government Program of Competitive Growth of Kazan Federal University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract